
LogicBio Therapeutics LOGC
Quarterly report 2022-Q3
added 11-14-2022
LogicBio Therapeutics Depreciation & Amortization 2011-2026 | LOGC
Annual Depreciation & Amortization LogicBio Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 626 K | 475 K | 289 K | 89 K | 43 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 626 K | 43 K | 304 K |
Quarterly Depreciation & Amortization LogicBio Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 508 K | 344 K | 166 K | - | 451 K | 286 K | 138 K | - | 349 K | 226 K | 105 K | - | 189 K | 104 K | 39 K | - | 49 K | 39 K | 9 K | - | 30 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 508 K | 9 K | 190 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Scholar Rock Holding Corporation
SRRK
|
1.66 M | $ 43.62 | -1.33 % | $ 5 B | ||
|
ARCA biopharma
ABIO
|
27 K | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
1 K | - | 10.36 % | $ 9.8 M | ||
|
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | ||
|
Arena Pharmaceuticals
ARNA
|
3.87 M | - | -6.81 % | $ 3.04 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M | ||
|
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | ||
|
bluebird bio
BLUE
|
28 M | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
7 K | - | 4.01 % | $ 150 M | ||
|
Avid Bioservices
CDMO
|
11.1 M | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
66 K | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
Stoke Therapeutics
STOK
|
1.77 M | $ 33.98 | 0.83 % | $ 2.01 B | ||
|
Autolus Therapeutics plc
AUTL
|
7.55 M | $ 1.23 | -5.04 % | $ 314 M | ||
|
EyePoint Pharmaceuticals
EYPT
|
2.31 M | $ 13.09 | 0.23 % | $ 959 K | ||
|
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B | ||
|
China SXT Pharmaceuticals
SXTC
|
82.3 K | $ 1.38 | 4.55 % | $ 1.96 M | ||
|
BioDelivery Sciences International
BDSI
|
140 K | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
259 K | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
3.14 M | - | - | $ 3.74 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
546 K | $ 1.07 | -2.29 % | $ 21.9 M | ||
|
Enochian Biosciences
ENOB
|
129 K | - | - | $ 40.5 M | ||
|
Equillium
EQ
|
116 K | $ 2.06 | - | $ 118 M | ||
|
Theravance Biopharma
TBPH
|
1.5 M | $ 14.97 | -1.45 % | $ 753 M | ||
|
Eton Pharmaceuticals
ETON
|
4.04 M | $ 23.43 | -0.09 % | $ 630 M | ||
|
CRISPR Therapeutics AG
CRSP
|
19.5 M | $ 47.18 | -0.79 % | $ 4.24 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
363 K | $ 4.46 | 0.22 % | $ 855 M | ||
|
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M |